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Introduction
As a referral center for children with unexplained autoin-
flammatory disease, the NIH sees a spectrum of patients
with previously unrecognized clinical syndromes. Here we
present one such case.
Objective
To describe a patient with unexplained fevers and a novel
clinical presentation.
Patients and methods
The patient is a 6 year-old boy referred from a small
town in Mexico. The patient was screened for mutations
in the known periodic fever syndrome genes by Sanger
sequencing. Whole genome SNP genotyping and whole
exome sequencing are under way.
Results
The patient was referred to our clinic for evaluation of
febrile episodes that started when he was 3 months old.
Fever was present every day, and was associated with a
rash that started in his feet and spread to his legs, with
irritability, abdominal pain, diarrhea, arthralgia, and arthri-
tis. During his first year of age, he was treated empirically
for multiple infections, but continued to have daily fevers.
As an infant, he underwent diagnostic testing for malig-
nancy and infectious diseases that were negative. At 18
months of age he was diagnosed with Still’s Disease. He
underwent multiple treatments, including oral steroids,
methotrexate, mycophenolate mofetil, etanercept and
intravenous cyclophosphamide, none of which relieved his
symptoms. When the patient was 3 years old he was
started on tocilizumab; the fevers evolved from daily to
episodic, occuring every 4 to 6 weeks and lasting 3 to 5
days. Genetic testing revealed a heterozygous M694I muta-
tion in the MEFV gene. At age 5 the patient developed sei-
zures. MRI of the brain showed hypo-intense lesions and
for this reason tocilizumab was discontinued with an
almost immediate return of his daily fevers and resolution
of the seizures. At NIH, he was found to have growth and
developmental delay, striking dysmorphic features includ-
ing microcephalus, coarse facies, muscle hypotonia, and
impressive joint hypermobility. He also displayed abnormal
behavior. He was febrile, irritable, and had a papular rash
in his feet and ankles; inflammatory markers were elevated.
After he started anakinra 4mg/Kg once a day, his fevers,
arthritis, and rash disappeared and his general status
improved dramatically. Further genetic analysis is pending.
Conclusions
At present it is unclear whether the patient’s fevers and
developmental abnormalities represent manifestations of a
common genetic lesion, or are independent phenotypes.
Although responsive to IL-1 inhibition, the fever syn-
drome appears atypical for FMF. Genomic analysis may
help to resolve these issues.
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